Key facts
- uMethod’s last known valuation is $55.0M (Sep 2024).
- It has raised $22.4M; the latest was Later Stage VC ($4.6M) in Dec 2025.
- Notable investors include Triangle Tweener Fund, Quartus Capital Partners, The Pink Ceiling.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for uMethod
- ·The full record, as it builds
Funding rounds
No funding rounds for uMethod are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About uMethod
Provider of evidence-based, personalized treatment plan services intended to treat chronic diseases. The company's treatment plans propose the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to a subgroup of patients, instead of a one-drug-fits-all model, enabling patients to get the customized care that they need to transform their lives.
- Sector
- Healthcare
- HQ
- Raleigh, NC, United States
- Founded
- 2013
- Employees
- 15
- Website
- umethod.com/
- Ownership
- Privately Held (backing)
uMethod doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in uMethod shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on uMethod in its N-PORT filings yet. We sweep new filings monthly.